Partners of the European Sepsis Academy
On this page you can find the various partners of the ESA
Biocartis aims to improve healthcare outcomes by enabling the practice of personalised medicine anywhere, anytime. Biocartis’ ambition is to establish a new gold standard in diagnostic testing and develops assays which have high clinical utility and compelling health economic value. Biocartis’ broad platform capabilities are well suited to address the growing need for individualised and primary care diagnosis. It is a rapidly growing company; to date staff includes over 180 people. Biocartis SA is based at the EPFL’s Innovation Square in Lausanne, Switzerland; the Belgian entity which counts over 100 staff, is located in Mechelen.Biocartis a.o. aims at the development of an integrated sample preparation platform (Polaris) for enabling molecular diagnosis starting from complex clinical samples such as large volumes of blood.
van Meerbergen, PhD – Polaris (renamed Idylla).
Program Manager at Biocartis. Former position included Senior Scientist at Philips Research and Marie Curie Post-doc at Philips Research.
European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
The European Society of Clinical Microbiology and Infectious Diseases is a non-profit organization whose mission is to improve the diagnosis, treatment and prevention of infection-related diseases. This is achieved by promoting and supporting research, education, training, and good medical practice. For more than 25 years, ESCMID has been an influential component in the professional lives of microbiologists and infectious disease specialists and now reaches more than 33’000 members and affiliated members around the world. ESCMID can be considered an educational centre since it is part of our mission to “promote and support research, education, training, and good medical practice”.
Jesús Rodríguez Baño, MD, PhD – ESCMID Education Officer and Coordinator of European Study Group on Bloodstream Infections and Sepsis (ESGBIS).
Chair of the Spanish Network for Research in Infectious Diseases. Head of the Infectious Diseases and Clinical Microbiology Department, Hospital Universitario Virgen Macarena (HUVM), Seville, Spain. Coordinator of local program of bacteraemia and sepsis, HUVM.
European Society of Intensive Care Medicine (ESICM)
The European Society of Intensive Care Medicine (ESICM) is a an international Scientific Society that aims to promote the highest standards of multidisciplinary care of critically ill patients and their families through education, research and professional development. For 30 years, the ESICM has developed scientific activities to foster research and education on all topics that pertain to intensive care medicine. The ESICM Trials Group has a strong experience in designing, conducting and publishing successful observational & interventional clinical trials in sepsis and acute respiratory failure. As of today, more than 40,000 patients have been recruited into clinical trials testing therapeutic interventions or observational studies by the 520 ICUs of the network.
Jacques Duranteau MD, PhD, is Professor of Anaesthesiology and Intensive Care Medicine at the University of Paris-Sud, Head of Surgical Intensive Care at the Kremlin Bicêtre Hospital and President of the Medical Committee of the University Hospitals of Paris-Sud. He has several mandates in the context of university and hospital management, as well as the teaching of students and specialist doctors in Anaesthesiology and Intensive Care. He is Chairman of the ESICM (European Society of Intensive Care Medicine) Research Committee and a member of SFAR (French Society of Anaesthesiology & Intensive Care) and SRLF (French Language Intensive Care Society).
Genomatix Software – Next-generation sequencing for personalized medicine program
Genomatix is one of the world’s leading suppliers of technologies to analyze and interpret genomic data. As well as laying the groundwork for microarray experiments and NGS data sequencing analyses, our hardware and software solutions also help to answer the typical questions posed by systems biology. Our approach: combine multiple lines of evidence to perform an integrated meta-analysis. Instead of looking at single strands of information separately, we access a large pool of data (curated and raw) from various sources which we continually keep up to date. This meta-analysis combined with our extensive biological background data leads to more relevant results, more precise scientific data interpretation and a better chance of understanding molecular contexts and mechanisms. Key Research facilities, infrastructure and equipment, include next Generation Sequencing data analysis, expression profiles, sequence and promoter analysis, proprietary genome annotation, Comparative genomics and the Genomatix Mining Station for mapping DNA methylation.
Martin Seifert (PhD) is a biologist and Managing Director of Genomatix.
His expertise is in chromatin IP, transcriptome analysis and nuclear receptors. His research focus within Genomatix is the development of efficient data analysis instruments for microarray and next generation sequencing data.
International Sepsis Forum (ISF)
The International Sepsis Forum (ISF) is a unique collaborative effort between industry and academia. It is the first initiative to focus solely on management of patients with severe sepsis. Headed by a Council of international experts and opinion leaders, the ISF is focused exclusively on improving the management of sepsis and, in particular, septic shock by developing an international consensus on the latest understanding of key scientific and clinical issues, and disseminating emerging practice guidelines to researchers, intensivists, and other critical care professionals worldwide. ISF can be considered an educational centre since it is part of our mission to promote “educating health professionals in the optimal management of patients with sepsis and raising the profile of sepsis as a global health challenge with the public.”
Elaine Rinicker – ISF Education Manager
Responsible for the organisation of educational courses and the yearly Summer School. Also responsible for scientific affairs (e.g. Study Groups, medical guidelines, etc.).
Luminex Corporation (NASDAQ: LMNX) was incorporated in May 1995 and began commercial production of its first generation system in 1997. Luminex develops, manufactures and markets innovative biological testing technologies with applications throughout the diagnostic and life science industries. The company’s open-architecture xMAP® and xTAG® Technologies enable large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately. Systems using xMAP technology perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer.
Jan van Gils BASc. Director Sales & Marketing Technology & Strategic Partnerships, Luminex Europe, ‘s-Hertogenbosch, The Netherlands. Former positions include Director , Sales and Marketing EMEA and India, Luminex Corporation and Director Technology and Strategic Partnerships EMEA and India, Luminex Corporation.
ttopstart is a European science and business consulting company specialised in technology transfer (hence the double t in ttopstart). ttopstart serves leading researchers and innovative companies in the fields of life sciences, medical technology and health with market research, business development and financing. The firms driver is the contribution to development of innovations that can strongly advance healthcare, such as diagnostics and treatments for a wide range of diseases with unmet medical needs as well as new healthcare delivery models. The company has access to different commercial and scientific databases for market analysis and strategic business development and has a strong European network in science and business. The company has different courses and in-house training programs for undergraduate and graduate students.
Jochem Bossenbroek MSc. – Partner ttopstart
Co-founder and co-owner of ttopstart. Bachelor Life Science & Technology at Leiden University and Delft University of Technology. Master in Management & Entrepreneurship in Health and Life Sciences at VU University Amsterdam. Contributed to the start of over 10 spin-off companies in the life sciences.
“This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 676129. This website reflects only the author’s view and the European Commission is not responsible for any use that may be made of the information it contains”